ArticleOman medical journal2025
HLA-DQ2 and HLA-DQ8 Haplotypes in Heart Failure Patients with Reduced Ejection Fraction.
Article in Oman medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between human leukocyte antigen-DQ2/DQ8 positivity and incident atrial fibrillation in patients with heart failure with reduced ejection fraction.Revista da Associacao Medica Brasileira (1992) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Genetic predisposition is one of the factors that contribute to the etiology of heart failure (HF). This study aimed to compare the prevalence of human leukocyte antigen (HLA)-DQ2 and HLA-DQ8 haplotypes in patients with HF with reduced ejection fraction (HFrEF) and healthy controls. Methods: This case control study was conducted in Western Türkiye, and included 100 participants: 50 patients diagnosed with HFrEF and 50 healthy matching controls. The frequency and distribution of HLA-DQ2 and HLA-DQ8 were compared between the groups. Results: No statistically significant differences in haplotype distribution were observed between patients and controls for any of the assessed parameters. HLA-DQ2 positivity was observed in 16.0% of the HFrEF group and 20.0% of controls, while HLA-DQ8 positivity was found in 24.0% and 26.0%, respectively. Subgroup analyses stratified by sex and HF etiology also did not reveal differences. Conclusions: The HLA-DQ2 and HLA-DQ8 haplotypes are not significantly associated with HFrEF in the population studied. Therefore, the utility of these haplotypes as standalone markers for early detection of HFrEF appears limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.